TABLE 2.
Plasma levels of microparticles in control patients and in patients with or without PDR
| Plasma |
Vitreous |
|||||
|---|---|---|---|---|---|---|
| Control | NPDR | PDR | Control | NPDR | PDR | |
| N | 26 | 6 | 28 | 26 | 6 | 28 |
| Annexin V+ microparticles | 1,223 (7–5,686) | 1,436 (130–2,871) | 721 (10–6,068) | 18 (0–633) | 9 (2–43) | 92 (2–1,349)*† |
| CD41+ microparticles | 765 (25–5,018) | 718 (68–1,763) | 408 (8–2,845) | 15 (0–156) | 12 (1–58) | 64 (2–728)*† |
| CD144+ microparticles | 98 (14–901) | 190 (31–609) | 89 (21–4,402) | 44 (0–378) | 52 (18–336) | 149 (13–900)*† |
| PNA+ microparticles | 0 | 0 | 0 | 6 (0–79) | 19 (0–64) | 17 (0–791) |
| ILB4+ microparticles | 0 | 0 | 0 | 0 (0–117) | — | 33 (0–184) |
Data are expressed as median (range) of microparticles/μl. Microparticles were identified of platelet (CD41+) and endothelial (CD144+) origin or from retinal origin (PNA+ and ILB4+). Annexin V+ microparticles express phosphatidyserine and were positively labeled with Annexin V. Microparticles levels were analyzed by Kruskall-Wallis nonparametric analysis followed by Mann-Whitney analysis of two groups when appropriate.
*†Significant difference between NPDR and PDR or between nondiabetic patients and patients with PDR, respectively.